Trials / Unknown
UnknownNCT05040984
Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Far Eastern Memorial Hospital · Academic / Other
- Sex
- Female
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
A retrospective analysis of medical records at Far Eastern Memorial Hospital from January 2008 to May 2020 about female patients with overactive bladder syndrome, who received Solifenacin or Mirabegron as the initial treatment. Factors affecting persistence of OAB medications will be analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Solifenacin Oral Tablet | Solifenacin 1 tablet per day |
| DRUG | Mirabegron 25mg | Mirabegron 1 tablet per day |
Timeline
- Start date
- 2021-04-30
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2021-09-10
- Last updated
- 2023-03-29
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT05040984. Inclusion in this directory is not an endorsement.